# A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease

> **NCT07640893** · PHASE2 · RECRUITING · sponsor: **Shanghai RAAS Blood Products Co., Ltd.** · enrollment: 24 (estimated)

## Conditions studied

- Von Willebrand Disease (VWD)

## Interventions

- **DRUG:** SR604

## Key facts

- **NCT ID:** NCT07640893
- **Lead sponsor:** Shanghai RAAS Blood Products Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-26
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07640893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07640893, "A Phase II Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of SR604 Injection in Patients With Von Willebrand Disease". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07640893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*